PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

of

27

<i>Con</i>	nplete if Known
Application Number	10/602,998
Filing Date	June 23, 2003
First Named Inventor	Thomas M. Brennan
Art Unit	1645 1637
Examiner Name	Unknown Chris Babic
Attorney Docket Number	28690-705.302

		U.S. PA	ATENT DOC	UMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
SAM		4,683,202	07/28/87	Mullis	
74.		4,834,946	05/30/89	Levin	
	· ·	5,143,854	09/01/92	Pirrung, et al.	
		5,202,231	04/13/93	Dramanac, et al.	
1		5,412,087	05/02/95	McGall, et al.	··· · · · · · · · · · · · · · · · · ·
		5,445,934	08/29/95	Fodor, et al.	
		5,445,943	08/29/95	Hoenes	
		5,474,796	12/12/95	Brennan	· · · · · · · · · · · · · · · · · · ·
		5,489,678	02/06/96	Fodor, et al.	
		5,492,806	02/20/96	Dramanac, et al.	
		5,525,464	06/11/96	Dramanac	
		5,545,568	08/13/96	Ellman	
		5,556,749	09/17/96	Mitsushashi, et al.	
		5,571,639	11/05/96	Hubbell, et al.	
		5,614,608	03/25/97	Krchnak, et al.	
		5,650,277	07/22/97	Navot, et al.	
		5,667,972	06/16/97	Dramanac, et al.	
		5,679,773	10/21/97	Holmes	
		5,691,141	11/25/97	Köster	

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code' - Number' - Kind Code' (If Innown)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
WY5		EP 717113A2	06/19/96	Affymetrix, Inc.		
, /		WO 92/15712	09/17/92	Molecular Tools, Inc.		·
		WO 93/09250	05/13/93	Adalaide Children's Hospital University of South Australia		
	*******	WO 93/17126	09/02/93	The Public Health Research Institute of the City		

Examiner Considered Signature

*EXAMINER: Initial if elements of the solution is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gog or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

FEB 0 2 2005 W

+

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

				Con	nplete if Known
Substitute fo	or form 144	9/PTO		Application Number	10/602,998
INFORM	INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	June 23, 2003	
			First Named Inventor	Thomas M. Brennan	
(Use as	many shee	ts as nece	ssary)	Art Unit	1645 1637
				Examiner Name	Unknown Chris Basic
Sheet	2	of	27	Attorney Docket Number	28690-705.302

		U.S. PA	ATENT DOC	UMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
(M)		5,695,940	12/09/97	Dramanac, et al.	
		5,700,637	12/23/97	Southern	
\neg		5,700,642	12/23/97	Monoforte, et al.	
		5,710,028	01/20/98	Eyal, et al.	
		5,739,386	04/14/98	Holmes	
		5,744,305	04/28/98	Fodor, et al.	
		5,800,992	09/01/98	Fodor, et al.	
		5,830,655	11/03/98	Monoforte, et al.	
\neg		5,837,832	11/17/98	Chee, et al.	
		5,846,943	12/08/98	Hindsgaul, et al.	
	-	5,858,653	01/12/99	Duran, et al.	
		5,858,659	01/12/99	Sapolsky, et al.	
		5,871,928	02/16/99	Fodor, et al.	
		5,888,819	03/30/99	Goelet, et al.	
		5,889,165	03/30/99	Fodor, et al.	
		5,917,016	06/29/99	Holmes	
		5,919,626	07/06/99	Shi, et al.	•
		5,922,534	07/13/99	Lichtenwalter	
		5,927,547	07/27/99	Papen, et al.	

Examiner Initials*	Cite No.	Foreign Patent Document Country Code' - Number' - Kind Code' (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
WS.		WO 95/11995	05/04/95	Affymax Technologies N.V.	
1		WO 97/28282	08/	Stratagene	
1		WO 97/43447	11/20/97	Motorola	
1		WO 97/45730	12/04/97	Biodx	
		WO 98/09735	03/12/98	International Business machine Corporation	

Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should, be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB c

				Complete if Known		
Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/602,998			
		Filing Date	June 23, 2003			
		First Named Inventor	Thomas M. Brennan			
(Use a	s many shee	ts as neces	sary)	Art Unit	1645- 1637	
				Examiner Name	Unknown Chris Basic	
Sheet	3	of	27	Attorney Docket Number	28690-705.302«CaseNumber»	

•	U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
MB		5,929,208	07/27/99	Heller, et al.					
1		5,972,619	10/26/99	Dramanac, et al.					
		5,985,551	11/16/99	Brennan					
		5,985,557	11/16/99	Prudent, et al.					
		5,985,761	11/16/99	Saprks, et al.					
		6,001,567	12/14/97	Brow, et al.					
		6,018,041	01/25/00	Dramanac, et al.					
		6,025,136	02/15/00	Drmanac					
		6,028,189	02/22/00	Blanchard					
		6,030,782	02/29/00	Anderson, et al.					
		6,040,138	03/21/00	Lockhart, et al.	•				
		6,043,031	03/28/00	Köster, et al.					
		6,054,270	04/25/00	Southern					
		6,074,823	06/13/00	Köster					
		6,083,763	07/04/00	Balch					
\dashv		6,090,995	07/18/00	Reich, et al.					
		6,103,479	08/15/00	Taylor					
		6,197,506	03/06/01	Fodor, et al.					
		6,210,894	04/03/01	Brennan					

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code' - Number' - Kind Code' (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
ans		WO 99/21957	05/06/99	The University of North Carolina at Chapel Hill		
Λ		WO 98/22487	05/28/98	Synsorb Biotech, Inc.	,	T
1		WO 98/28438	07/02/98	Diatech Pty. Ltd.		T
-		WQ 98/30883	07/16/98	Sheldon, Edward L.	 	T

*EXAMINER: Initial if reference onsidered, whether or per citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.91 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form. call 1-800-PTO-9199 (1-800-786-9199) and select option 2

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

STATEMENT BY APPLICANT
(Use as many sheets as necessary)

Sheet 4 of 27 Attorney Docket Number 28690-705.302

		U.S. PA	ATENT DOC	UMENTS	
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
		Number-Kind Code ² (if known)			Figures Appear
CMB		6,291,183	09/18/01	Pirrung, et al.	
1		6,309,822	10/30/01	Fodor, et al.	
		6,309,823	10/30/01	Cronin, et al.	
		6,309,831	10/30/01	Goldberg, et al.	
1		6,310,189	10/30/01	Fodor, et al.	

Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	1
aws.		WO 98/38490	09/03/98	Biodx, Inc.	recevant rigares represe	╁╴
, ,		WO 98/38846	09/11/98	Affymetrix, Inc.		t
$\neg \vdash$		WO 98/41531	09/24/98	University of Washington		\dagger
		WO 98/46247	10/22/98	Wisconsin Alumni Research Foundations		T
		WO 98/47003	10/22/98	United States of America		T
		WO 98/50403	11/12/98	THIRD WAVE TECHNOLOGIES, INC.		T
		WO 98/54362	12/03/98	The Perkin-Elmer Corporation		
		WO 98/56954	12/17/98	Affymetrix, Inc .		T
		WO 99/05308	02/04/99	RAPIGENE, INC.		T
		WO 99/06593	02/11/99	Sarnoff Corporation		
		WO 99/06834	02/11/99	IXSYS, Incorporated		Ť
		WO 99/07888	02/18/99	Bulynk, Martha L.		t
		WO 99/09073	02/25/99	Akazo Nobel N.V.		T
		WO 98/21221	05/22/98	Synsorb Biotech, Inc		t
1.		WO 94/11530	05/26/94	Trustees of Boston University		T
		WO 93/17136	09/02/93	The Dow Chemical Company		
		WO 98/33586	08/06/98	Protogene Laboratories, Inc.		

*EXAMINER: Initial in reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if notin conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. It ind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

				Con	nplete if Known
Substitute for form 1449/PTO INFORMATION DISCLOSURE		Application Number	10/602,998		
		Filing Date	June 23, 2003		
STATE	STATEMENT BY APPLICANT		First Named Inventor	Thomas M. Brennan	
(Use a	s many shee	ts as nec	cessary)	Art Unit	1645 1637
				Examiner Name	Unknown Chris Basic
Sheet	5	of	27	Attorney Docket Number	28690-705.302

Examiner Cite Initials No.		Foreign Patent Document Country Code' - Number' - Kind Code' (if known)	MM-DD-YYYY		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
MC3		WO 99/14228	03/25/99	Affymetrix, Inc		
1/		WO 99/27137 ·	06/03/99	Orchid Biocomputer, Inc.		T
		WO 99/37812	07/29/99	Orchid Biocomputer, Inc		T
		WO 99/39004	08/05/99	The government of the United States of America, Secretray, Department of Health and Human Services	2	
		WO 99/47701	09/23/99	November AG Novus Medicatus Bertling Gesellschaft fur Molekulare Medizin		
		WO 99/54509	10/28/99	Affymetrix, Inc.		T
		WO 99/58708	11/18/99	Rosetta Inpharmatics, Inc		T
		WO 00/03246	01/20/00	Cellomics, Inc.		T
		WO 00/17624	03/30/00	Cellomics, Inc.		T
- /		WO 00/17643	03/30/00	Cellomics, Inc.		T
-		WO 00/50872	08/31/00	Cellomics, Inc.		T

*EXAMINER: Initial il reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not if conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. The Toffice that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number

				Com	plete if Known
Substitute t	for form 14	49/PTO		Application Number	10/602,998
			LOSURE	Filing Date	June 23, 2003
			LICANT	First Named Inventor	Thomas M. Brennan
(Use	as many shee	eis as nec	essary)	Art Unit	1645- 1637
				Examiner Name	Unknown Chris Basic
Sheet	6	of	27	Attorney Docket Number	28690-705.302

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
JMB)	i	ABRAMSON et al., Nucleic acid amplification technologies, Curr. Opin. Biotechnol., 1993, pp.41-47, vol. 4	
		ABRAVAYA et al., Detection of poinT mutations with a modified ligase chain reaction, Nucleic Acids Res., 1995, pp 675-682, vol 23	
		ADINOLFI et al., Solid Phase Synthesis of Oligosaccharides, Tetrahedron Lett., 1996, pp 5007-5010, 37 (28)	
		ALBERICIO et al., Covergrent Solid-Phase Peptide Synthesis, Methods Enzymol, 1997, pp 313-316, vol 289	
		ANDRES et al., Transistion metal mediated reactions in combinatorial synthesis, Curr. Opin. Chem. Biol., 1998, pp353-362, vol 2	
		ATHERTON et al., Solid Phase Peptide Synthesis, A practical approach, IRL press, 1989,	
		AUSUBEL et. al., Current Protocols in Molecular Biology, John Wiley & Sons, 1989, vol. 1-2	
		BEIER et. al., Versatile Derivatisation of solid support media for covalent bonding on DNA-microchips, Nucleic Acids Res., 1999, pp 1970-1977, vol. 27 (9)	

Examiner Date signature Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including the complete and the public which is to complete including the complete and the public which is to complete including the complete and the public which is to complete including the complete and the public which is to complete including the complete and the public which is to complete and the public which is to complete including the complete and the public which is to file (and by the USPTO Time will want described to the public which is to complete and the public which is to complete the public which is to file (and by the USPTO Time will want described to the public which is to file (and by the USPTO Time will want described to the public which is to file (and by the USPTO Time will want described to the public which is to file (and by the USPTO Time will want described to the public which is to file (and by the USPTO Time will want described to the public which is to file (and by the USPTO Time will want described to the public which is to file (and by the USPTO Time will want described to the public which is to file (and by the USPTO Time will want described to the public which is to file (and by the USPTO Time will want described to the public which is to file (and by the USPTO Time will want described to the public which is to file (and by the USPTO Time will want described to the public which is to file (and by the USPTO Time will want described to the public which is to file (and by the USPTO Time will want described to the public which is to file (and by the USPTO gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

				Com	plete if Known
Substitute f	or form 144	9/PTO		Application Number	10/602,998
1			CLOSURE	Filing Date	June 23, 2003
•			PLICANT	First Named Inventor	Thomas M. Brennan
(Use	as many shee	is as ne	cessary)	Art Unit	1645 1637
			Examiner Name	Unknown Chris Basic	
Sheet	7	of	27	Attorney Docket Number	28690-705.302

		NON PATENT LITERATURE DOCUMENTS				
Examiner Cite No.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
		BLANCHARD et. al., Syntheic DNA Arrays, Biosenors and Bioelectronics, 1996, pp 687-690, vol. 11				
		BLIXT et. al., Solid-Phase Enzymatic Synthetic of a Sialy Lewis X Tetrassaccharide on a Sepharose Matrix, J. Org. Chem., 1998, pp.2705-2710, vol. 63				
		BRZOSKA et. al., Evidence of a transistion temperature for the optimum depostion of grafted monolayer coatings, Nature, 1992, pp 719-721, 360				
		BUHR et. al., Oligodeoxynucleotides containing C-7 propyne analogs of 7-deaza 2'-deoxyguanosine and 7-deaza-2'-deoxyadenosine, Nucleic Acids Res., 1996, pp 2974-2980, 24 (15)				
		BULYK et. al., Quantifying DNA-protein interactions by double-stranded DNA arrays, Nature Biotechnology, 1999, 573-577, 17				
	,	BURG et. al., Real-Time Fluorescense Detection of RNA Amplified by QB Replicase, Anal. Biochem., 1995, pp263-272, vol. 230				
		CANTOR and SCHIMMEL et. al., Part 1: The conformation of biological macromolecules, Biophycical Chemistry, San Francisco, W.H. Freeman, 1980				

Examiner signature	Ma	al	Date Considered	4/	12/05
		•		. /	/

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

			•	Complete if Known		
Substitute 1	for form 144	49/PTO		Application Number	10/602,998	
INFORM	MATION	DISC	LOSURE.	Filing Date	June 23, 2003	
	STATEMENT BY APPLICANT			First Named Inventor	Thomas M. Brennan	
(Use	as many shee	is as nec	essary)	Art Unit	1645 IG37	
				Examiner Name	Unknown Chris Basic	
Sheet	8	of	27	Attorney Docket Number	28690-705.302	

Examiner Cite No. 1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
		CASE-GREEN et. al., Analyzing genetic information with DNA arrays., Cur. Opin. In Chem. Biol., 1998, pp 404-410, vol. 2				
		CZARNIK, et. al., Guest Editorial, Accounts Chem. Rev., 1996, pp112-170, vol. 29	-			
		DANISHEFSKY et. al., A Stategy for the Solid-Phase Synthetic of Oligosaccharides, Science, 1993, pp1307-1309, vol 260				
		DERISI, et. al., Exploring the Metabolic and Genetic Control of Gene Expression on A Genomic Scale, Science, 1997, pp680-686, vol 278				
		DE WILDT et. al., Antibody arrays for high-throughput screening of antibody-antigen interactions, Nature, 2000, pp 989, vol. 18	,			
		DRMANAC et. al., Sequencing of Megabase Plus DNA by Hybridization: Theory of the Method, Genomics, 1989, pp114-28, vol 4				
		DRMANAC et. al., Accurate sequencing by hybridization for DNA diagnostics and individual genomics, Nature Biotechnology, 1998, pp 54-58, vol 16				
		DE WILDT et. al., Antibody arrays for high-throughput screening of antibody-antigen interactions, Nature, 2000, pp 989, vol. 18				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Date

Considered

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Examiner

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a would OMB of

				Complete if Known		
Substitute 1	for form 14	49/PTO		Application Number	10/602,998	
			CLOSURE	Filing Date	June 23, 2003	
			PLICANT	First Named Inventor	Thomas M. Brennan	
(Use	as many she	els as nec	cessary)	Art Unit	1643 1637	
				Examiner Name	Unknown Chris Basic	
Sheet	9	of	27	Attorney Docket Number	28690-705.302	

			NON PATENT LITERATURE DOCUMENTS	
	Examiner Cite No. 1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
UM.			DRMANAC et. al., Sequencing of Megabase Plus DNA by Hybridization: Theory of the Method, Genomics, 1989, pp114-28, vol 4	
1			DRMANAC et. al., Accurate sequencing by hybridization for DNA diagnostics and individual genomics, Nature Biotechnology, 1998, pp 54-58, vol 16	
			DUGGAN et. al., Expression profiling using cDNA microarrays, Nature Genetics Supplement, 1999, pp 10-14, 21	
			ECKERT et al., DNA Polymerase Fidelity and the Polymerase Chain Reaction, PCR Methods and Applications, 1991, pp17, vol 1	
			EDMAN et al., Electric field directed nucleic acid hybridization on microchips, Nucleic Acids Research, 1997, pp 4907-4914, vol. 25(24)	
			EISENBERG et al., Protein function in the post-genomic era, Nature, 2000, pp 823-826, vol. 405	
			FODOR et al., Light-Directed, Spatially Addressable Parallel Chemical Synthesis, Science, 1991, pp 767-773, vol 251	
			DE WILDT et. al., Antibody arrays for high-throughput screening of antibody-antigen interactions, Nature, 2000, pp 989, vol. 18	

Examiner	1		Date	1// 1	2/2
signature	/ W	\mathcal{M}	Considered	4//	2/03
		-			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

				Complete if Known		
Substitute f	for form 144	19/PTO		Application Number	10/602,998	
			LOSURE	Filing Date	June 23, 2003	
			LICANT	First Named Inventor	Thomas M. Brennan	
(Use	as many shee	ets as neces	ssary)	Art Unit	+645 1637	
				Examiner Name	Unknown Chris Basic	
Sheet	10	of	27	Attorney Docket Number	28690-705.302	

_		NON PATENT LITERATURE DOCUMENTS							
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.							
		DRMANAC et. al., Sequencing of Megabase Plus DNA by Hybridization: Theory of the Method, Genomics, 1989, pp114-28, vol 4							
	·	DRMANAC et. al., Accurate sequencing by hybridization for DNA diagnostics and individual genomics, Nature Biotechnology, 1998, pp 54-58, vol 16							
		DUGGAN et. al., Expression profiling using cDNA microarrays, Nature Genetics Supplement, 1999, pp 10-14, 21							
		ECKERT et al., DNA Polymerase Fidelity and the Polymerase Chain Reaction, PCR Methods and Applications, 1991, pp17, vol 1							
		EDMAN et al., Electric field directed nucleic acid hybridization on microchips, Nucleic Acids Research, 1997, pp 4907-4914, vol. 25(24)							
		EISENBERG et al., Protein function in the post-genomic era, Nature, 2000, pp 823-826, vol. 405							
		FODOR et al., Light-Directed, Spatially Addressable Parallel Chemical Synthesis, Science, 1991, pp 767-773, vol 251							
		FRUCHTEL, Organic Chemistry and Solid Supports, Angew. Chem. Int. Ed. Engl., 1996, pp17-42, vol. 35							

		// .				<i>(</i>	
Examiner signature		1	fr	Date Considered	4/	121	05
	1 10 12	,		 		/	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO). to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number

				Complete if Known					
Substitute for	or form 144	9/PTO		Application Number	10/602,998				
			CLOSURE	Filing Date	June 23, 2003				
	STATEMENT BY APPLICANT			First Named Inventor	Thomas M. Brennan				
(Use a	s many shee	is as ne	cessary)	Art Unit	1643 1637				
·				Examiner Name	Unknown Chris Besic				
Sheet	Sheet 11 of 27		Attorney Docket Number	28690-705.302					

		NON PATENT LITERATURE DOCUMENTS						
Examiner Cite No.!		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s						
		GELFAND et. al., ASDB: database of alternatively spliced genes, Nucleic Acids Res., 1999, pp.301-302, vol. 27(1)						
		GERHOLD et al, DNA chips: promising toys have become powerful tools, TIBS, 1999, pp168-173, vol. 24	-					
		GIBSON et al, A Novel Method for Real Time Quantitative RT-PCR, Genome Res., 1996, pp995-1001, vol. 6						
	·	GIESEN et al., A formula for thermal stability (Tm) prediction of PNA/DNA duplexes, Nucleic Acids Research, 1998, pp. 5004-5006, vol. 26(21)						
		GOOD et al., Antisense inhibition of gene expression in bacteria by PNA targeted to mRNA, Nature Biotechnology, 1998, pp. 355-358, vol. 16						
		GORDON et al., Combinatorial Chemistry and Molecular Diversity in Drug Discovery, 1997, John Wiley & Son, New York						
		GORDON et al., Applications of Combinatorial Technologies to Drug Discovery. 2. Combinatorial Organic Synthesis, Library Screening Strategies, and Future Directions, J. Med. Chem., 1994, pp 1385-1401, vol. 37						
		GRANT et al., Human acetyltransferase polymorphisms, Mut. Res., 1997, pp 61-70, vol. 376						

			<i>1</i>
Examiner		Date //	1 . 1 05
signature	1/1/10	Considered 4/	12/00
	111		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO). to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

				Complete if Known					
Substitute	for form 14	19/PTO		Application Number	10/602,998				
			LOSURE	Filing Date	June 23, 2003				
	STATEMENT BY APPLICANT			First Named Inventor	Thomas M. Brennan				
(Use	as many she	els as nec	essary)	Art Unit	1645 1637				
	·			Examiner Name	Unknown Chris Besic				
Sheet	12	of	27	Attorney Docket Number	28690-705.302				

Examiner Cit Initials* No.		T²
cm7	GREENBERG et al., Cleavage of Oligonucleotides from Solid-Phase Using o- Nitrobenzyl Photochemistry, J. of Org. Chem., 1994, pp 746-753, vol. 59	
	GREENBERG, Photochemical Release of Protected Oliucleotides Contatining 3'- Glycolate Termini, Tetrahedron, 1995, pp 29-38, vol. 51	
	GREENBERG, Photochemical Cleavage of Oligonucleotides From Solid Phase Supports, Tetrahedron Lett., 1993, pp 251-254, vol. 34	,
	GURURAJA et al., Solid-Phase Synthesis of Human Salivary Mucin-Derived Olionked Glycopeptide, Lett Pept. Sci., 1996, pp 79-88, vol. 3	
·	GUSCHIN et al., Manual Manufacturing of Oligonucleotide, DNA, and Protein Microchips, Anal. Biochem., 1997, pp 203-211, vol. 250	•
	HAMMER et al., Practical Approach to Solid-Phase Synthesis of C-terminal Peptide Amides under Mild Conditions Based on a Photolysable Anchoring Linkage, J. Peptide Protein Res., 1990, pp. 31-45, vol. 36	
	HECKEL et al., Oligosaccharide Synthesis on Controlled-Pore Glass as Solid Phase Material, Synlett, 1998, pp. 171-173	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 10/602,998 INFORMATION DISCLOSURE Filing Date June 23, 2003 STATEMENT BY APPLICANT First Named Inventor Thomas M. Brennan (Use as many sheets as necessary) Art Unit **Examiner Name** Attorney Docket Number 28690-705.302 Sheet 13 of 27

Examiner Initials*	Cite No. 1	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
CM3	NO.	HEID et al., Real Time Quantitative PCR, Genome Res., 1996, pp. 986-994, vol. 6	1-
		HERMKENS et al., Solid-Phase Organic Reactions: A review of the Recent Literature, Tetrahedron, 1996, pp. 4527-4554, vol. 52	
	•	HIGUCHI et al., Simultaneous Amplification and Detection of Specific DNA Sequences, Bio/Technology, 1992, pp. 413-417, vol. 10	
		HIGUCHI et al., Kinetic PCR Analysis: Real-time Monitoring of DNA Amplification Reaction, Bio/Technology, 1993, pp. 1026-1030, v	
		HOLMES et al., Reagents for Combinatorial Organic Synthesis: Development of a New o-Nitrobenzyl Photoabile Linker for Solid Phase Synthesis, J. of Org. Chem., 1995, pp.2318-2319, vol. 60	
		HOLMES et al., Model Studies for New o-Nitrobenzyl Photolabile Linkers: Substituent Effects on the Rates of Photochemical Cleavage, J. of Org. Chem., 1997, pp 2370-2380, vol. 62	
	-	HUGHES et al., Functional Discovery via a Compendium of Expression Profiles, Cell, 2000, pp. 109-126, vol. 102	
Examiner	<u> </u>		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional).

²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

				Complete if Known				
Substitute	for form 14	49/PTO		Application Number	10/602,998			
INFOR	MATION	DISCI	LOSURE	Filing Date	June 23, 2003			
	STATEMENT BY APPLICANT			First Named Inventor	Thomas M. Brennan			
(Use	as many she	eis as nece.	ssary)	Art Unit	1645 1637			
•	•			Examiner Name	Unknown Chris Besic			
Sheet	14	of	27	Attorney Docket Number	28690-705.302			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Cite Initials* No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ² ·
cmB		HYNDMAN et al., Software to Determine Optimal Oligonucleotide Sequences Based on Hybridization Simulation Data, BioTechniques, 1996, pp 1090-1097, vol. 20(6)	
		ISHIGURO et al., Homogeneous Quantitative Assay of Hepatitis C Virus RNA by Polymerase Chain Reaction in the Presence of a Fluorescent Intercalater, Anal. Biochem., 1995, pp. 207-213, vol. 229	
		ISAKSSON and LANDEGREN, Accessing genomic information: alternatives to PCR, Curr. Opin. Biotechnol., 1999, pp. 11-15, vol. 10	,
		ITO et al., Solid-phase oligosaccharide synthesis and related technologies, Curr. Opin. Biotechnol., 1998, pp. 701-708, vol. 2	
		JOOS et al., Covalent Attachment of Hybridizable Oligonucleotides to Glass Supports, Anal. Chem., 1997, pp 96-101, vol. 247	
		KAHL et al., High-Yielding method for On-Column Derivatization of Protected Oligodeoxy-nucleotides and Its Application to the Convergent Synthesis of 5', 3'-Bisconjugates, J. of Org. Chem., 1998, pp 4870-4871, vol. 63	

		亼	_	_		<u> </u>	<u> </u>				
Examiner				7	6 1			Date	4	112	100
signature		_		_		~く	_	Considered		12	105
	7	,	7	_							

*EXAMINER: Initial it reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE o a collection of information unless it contains a valid OMB control number.

				Complete if Known				
Substitute	for form 14	49/PTO		Application Number	10/602,998			
INFORM	MATION	DISCI	LOSURE	Filing Date	June 23, 2003			
	STATEMENT BY APPLICANT			First Named Inventor	Thomas M. Brennan			
(Use	as many shee	eis as nece.	ssary) .	Art Unit	1645 1637			
				Examiner Name	Unknown Chris Besic			
Sheet	15	of	27	Attorney Docket Number	28690-705.302			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
curb		KAHL and GREENBERG, Solution-Phase Bioconjugate Synthesis Using Protected Oligonucleotides Containing 3'-Alkyl Carboxylic Acis, J. of Org. Chem., 1999, pp 507-510, vol. 64	
		KAHN et al., Modern Methods in Carbohydrate Synthesis, Harwood Academic, 1996, Amsterdam	
		KIERZEK et al., Association of 2'-5' oligoribonucleotides, Nuclein Acids Research, 1992, pp 1865-1690, vol. 20(7)	
		KIHLBERG et al., Direct Synthesis of Glycosylated Amino Acids from Carbohydrate Peracetates and Fmoc Amino Acids: Solid-Phase Synthesis of Biomedicinally Interesting Glycopeptides, Methods Enzymol., 1997, pp 221-245, vol. 289	
		KROKAN et al., DNA glucosylases in the base excision repair of DNA, Biochem, 1997, 1-16, vol.325	
		KUPPUSWAMI, et al., Single nucleotide primer extension to detect genetic diseases: Experimental application to hemophilia B (faxtor IX) and cystic fibrosis genes, Proc. Natl. Acad. Sci. USA, 1991, pp. 1143-1147, vol. 88	

Examiner signature	1 Int	Date Considered	4/12/05
	<u> </u>		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

				Complete if Known		
Substitute	for form 144	19/PTO		Application Number	10/602,998	
			LOSURE	Filing Date	June 23, 2003	
	STATEMENT BY APPLICANT (Use as many sheets as necessary)			First Named Inventor	Thomas M. Brennan	
(Use	as many snee	is as nec	essary)	Art Unit	1645 1637	
				Examiner Name	Unknown Chris Basic	
Sheet	16	of	27	Attorney Docket Number	28690-705.302«CaseNumber»	

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	
OMG	No. ¹	publisher, city and/or country where published. LANDGREN, et al., The Challengers to PRC: a proliferation of chain reactions, Curre. Opin. Biotechnol., 1996, pp95-97, vol. 7	T²
		LANDGREN, et al., Reading Bits of Genetic Information: Methods for Single-Nucletide Polymorphism Analysis, Genome Research, 1998, 769-776, vol. 8	
		LIE, et al, Advances in quantitative PCR technology 5' nuclease assays, Curr. Opin. In Biotech., 1998, pp43-48, vol.9	
		LIN, et al, Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene, Pharmacogenetic, 1994, pp. 125-134, vol. 4	
	-	LIPSHUTZ, et al, High density synthetic oligonucleotide arrays, Nature Genetics Supplement, 1999, pp 20-24, vol. 21	
		LIVAK, et al, Oligonucleotides with Fluorescent Dyes at Opposite Ends Provide a Quenched Probe System Useful for Detecting PCR Product and Nucleic Acid Hybridization, PCR Methods and Applications, 1995, pp 357-362, vol.4	
		LLOYD-WILLIAMS, et al., Convergent Solid-phase peptide synthesis, Tetrahedro, 1993, pp 11065-11133, vol. 49	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with part comprunication to applicant

Date

Considered

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option

Examiner

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number

				Com	plete if Known
Substitute f	or form 14	19/PTO		Application Number	10/602,998
			LOSURE	Filing Date	June 23, 2003
			LICANT	First Named Inventor	Thomas M. Brennan
(Use a	as many shee	ets as nece	ssary)	Art Unit	1645 1637
				Examiner Name	Unknown Chris Basic
Sheet	17	of	27	Attorney Docket Number	28690-705.302«CaseNumber»

xaminer nitials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
mB		LOCKHART, et al, Genomics, gene expression and NDA arrays, Nature, 2000, pp827-936, vol. 405	
		MALEK et al, Nucleic Acid Sequence-Based Amplication (NASBA), Methods Mol. Biol, 1994, pp 253-260, vol. 28	
		MASKO, et al., Oligonucleotide hydridisations on glass supports: a novel linker for oligonucleotide synthesis and hydridisation properties of oligonucleotides synthesised in situ, Nucleic Acids Research, 1992, pp1679-1684, vol.20(7)	
		MATTILA et al., Fidelity of DNA Synthesis by the Thermococcus litoralis DNA polymerase-an extremely heat stable enzyme with proofreading activity, Nucleic Acids Res, 1991, pp 4967-4973, vol. 19(18)	
	•	McDEVITT et al., Glycosamino Acids: New Building Blocks for Cominatorial Synthesis, J. Am. Chem. So, 1996, pp 3818-3828, vol. 118	
		McKENZIE, et al., Parallel molecular genetic analysis, European Journal of Human Genetics, 1998, pp 417-429, vol. 6	
		McMINN et al., Efficient Solution Phase synthesis of Oligonucleotide Conjugates Using Protected Biopolymers Containing 3'-Terminal Alkylamines, J. of Org. Chem, 1997, pp7074-7075, vol. 62	

W *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is unique citation designation number (optional).

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

				Complete if Known		
Substitute 1	or form 14	49/PTO		Application Number	10/602,998	
INFORM	LATION	DISCI	LOSURE	Filing Date	June 23, 2003	
	STATEMENT BY APPLICANT			First Named Inventor	Thomas M. Brennan	
(Use	as many she	eis as nece:	ssary)	Art Unit	1645 1637	
				Examiner Name	-Unknown Chris Bosic	
Sheet	18	of	27	Attorney Docket Number	28690-705.302	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
CMP	2	McMINN et al., Novel Solid Phase Synthesis Supports for the Preparation of Oligonucleotides Containing 3'-Alkyl Amines, Tetrahedron, 1996, pp 3827-3840, vol.52	
		MELDAL, et al., Synthetic methods for glycopeptide assembly, and biological analysis of glycopetide products, Curr. Opin. Chem. Biol, 1997, pp 552-563, vol. 1	
		MERRIFIELD, Solid-Phase Synthesis, Science, 1986, pp 342-347, vol. 232	
		METHODS MOL. BIOL, Protocols for Oligonucleotides and Analogs, ed. Sudhir Agrawal, 1984, Vol. 20	
		MITSUHASHI, Technical Report: Part 1. Basic Requirements for Designing Optimar Oligonuclotide Probe Sequences, J. Clinical Laboratory Analysis, 1996, pp 277-284, vol 10	
		MRKSICH, et al, Controlling cell attachment on contoured surfaces with self-assembled monlayers of alkanethiolates on gold, Proc. Natl. Acad. Sci, 1996, pp 10775-8, vol. 93	
		MRKSICH, et al, Using Self-Assembled Monolayers to understand the interactions of man-made surfaces with proteins and cells, Ann. Rev. Biophys. Biomol. Struct., 1996, pp 55-78, vol. 25	

Examiner Date signature Considered

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

				Comp	plete if Known
Substitute 1	or form 14	49/PTO		Application Number	10/602,998
INFORM	IATION	DISC	LOSURE	Filing Date	June 23, 2003
			LICANT	First Named Inventor	Thomas M. Brennan
(Use	as many shee	eis as nece	essary)	Art Unit	1645 (637
				Examiner Name	Unknown Chris Besic
Sheet	19	of	27	Attorney Docket Number	28690-705.302«CaseNumber»

<u>-</u>		NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	
Examiner Initials*	Cite No.1	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
OMB/		MULLER et al, Self-sustained sequence replication (3SR): An alternative to PCR, Histochem. Cell Biol., 1997, pp 431-437, vol. 108	
	·	NELSON, Rapid Detection of Genetic Mutations Using the Chemiluminescent Hybridization Protection Assay (HPA): Overview and Comparison with Other Methods, Crit. Rev. Clin. Lab. Sci., 1998, pp 369-414, vol. 35	
		NICOLAOU et al, A General and Highly Efficient Solid Phase Synthesis of Oligosaccharides, J Am. Chem. Soc., 1998, pp 449-450, vol. 119	
		NIELSEN, Applications of peptide nucleic acids, Current Opinion in Biotechnology, 1999, pp71-75, vol. 10	
		NGUYEN, et al, Modification of DNA duplexes to smooth their thermal stability independently of their base content for DNA sequencing by hybridization, Nucleic Acids Research, 1997, pp 3059-3065, vol 25(15)	
		NGUYEN, et al, The stability of duplexes involving AT and/or G(4et)C base pairs is not dependent on their AT/G(4et)C ratio content. Implication for DNA sequencing by hybridization, Nucleic Acids Research, 1998, pp 4249-4259, vol. 26(18)	
		PANDEY, et al, Proteomics to study genes and genomes, Nature, 2000, pp 837-846, vol. 405	
Examiner signature		Date Considered 4 12 05	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

				Com	plete if Known		
Substitute 1	for form 144	19/PTO		Application Number	10/602,998		
			LOSURE	Filing Date	June 23, 2003		
			LICANT	First Named Inventor	Thomas M. Brennan		
(Use	as many shee	is as nec	essary)	Art Unit	1645- 1637		
			•	Examiner Name	Unknown Chris Basic		
Sheet	20	of	27	Attorney Docket Number	28690-705.302«CaseNumber»		

Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
l MB		PAULSEN et al, New solid-phase oligosaccharide synthesis on glycopeptides bound to a solid phase, J. Chem. Perkin Trans, 1997, pp 281-293, vol. 1	
		PCR, A Practical Approach, eds. McPherson et al., IRL Press, Oxford, 1991	
		PCR2, A Practical Approach, eds. McPherson et al., IRL Press, Oxford, 1995	
	_	PCR, Protocols: A Guide to Methods and Applications, eds. Innis, et al., Academic Press, San Diego, CA, 1990	
		PCR, Technology: Principles and Applications for DNA Amplification, ed. H.A. Erlich, Freeman Press, NY, NY, 1992	
		PONTIUS, et al., Rapid renaturations of complementary DNA strands mediated by cationic detergents: A role for high-probability binding domains in enhancing the dinetics of molecular assembly processes, Proc. Natl. Acad. Sci. USA, 1991, pp 8237-8241, vol. 88	
		RADEMANN et al, Repetitive SolidPhase Glycosylation ona an Alkyl Thiol Polymer Leading to Sugar Oligomers Containing 1, J Org. Chem, 1997, pp 3650-3653, vol. 62	

Examiner signature		In	Date Considered	4/	12/05
	1 ///			1.1	

^{*}EXAMINER: Initial if elemence considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO providers) and the complete including the complete i to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

				Complete if Known			
Substitute f	or form 144	9/PTO		Application Number	10/602,998		
			CLOSURE	Filing Date	June 23, 2003		
			PLICANT	First Named Inventor	Thomas M. Brennan		
(Use a	is many shee	is as ne	cessary)	Art Unit	1645 1637		
				Examiner Name	Unknown Chris Basic		
Sheet	21	of	27	Attorney Docket Number	28690-705.302		

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
oney		REES, et al., Betaine Can Eliminate the Base Pair Composition Dependence of DNA Melting, Biochemistry, 1993, pp 137-144, vol. 3				
		RICH, et al., Preparation of a New o-Nitrobenzyl Resin for Solid-Phase Synthesis of tert-Butyloxycarbonl-Protected Peptide Acids, J. Am. Chem. Soc, 1975, pp 1575-1579, vol. 97				
		RICH, et al, Removal of Protected Peptides from an ortho-nitrobenzyl resin of photolysis, J.C.S. Chem. Comm, 1973, pp610-611				
		ROBERTS, et al., Signaling and Circuitry of Multiple MAPK Pathways Revealed by a Matrix of Global Gene Expression Profiles, Science, 2000, pp878-880, vol. 287				
		RODEBAUGH et al, Polymer-Supported Oligosaccharides via n-Pentenyl Glycosides: Methodology for a Carbonhydrate Library, J. Org. Chem, 1997, pp5660-5661, vol. 62				
		RYCHLIK, et al., A computer program for choosing optimal oligonucleotides for filter hybridization, sequencing and in vitro amplification of DNA, Nucleic Acids Res, 1989, pp8543-8551, vol. 17				
ľ		RYCHLIK, et al., Optimization of the annealing temperature for DNA amplification in vitro, Nucleic Acids Res, 1989, pp6409-6412, vol. 18(21)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

		_ , ,		Complete if Known			
Substitute for form 1449/PTO				Application Number	10/602,998		
INFORM	MATION	DISCI	LOSURE	Filing Date	June 23, 2003		
			LICANT	First Named Inventor	Thomas M. Brennan		
(Use	as many she	eis as nece	ssary)	Art Unit	1645 [637		
				Examiner Name	Unknown Chris Basic		
Sheet	22	of	27	Attorney Docket Number	«CaseNumber»28690-705.302		

-		NON PATENT LITERATURE DOCUMENTS					
Examiner Cite Initials* No. 1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
(me)		SAMBROOK et al, Molecular Cloning: A Laboratory Manual, 2" Ed, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989					
		SCHENA et al., Microarrays: biotechnology's discovery platform for functional geneomics, TIBTECH, 1998, pp. 301-306, vol. 16					
		SCHULLEK, et al, A High-density Screening format for Encoded Combinationial Libraries: Asssay Miniaturization and Its Application to Enzymatic Reactions, Anal. Biochem, 1997, pp20-29, vol. 246					
	-	SHUSTER et al., Solid-Phase Chemical-Enzymatic Synthesis of Glycopeptides and Oligosaccharides, J Am. Chem. Soc, 1994, pp1135-1136, vol. 116					
		SILVERIA and ORGEL, PCR with detachable primers, Nucleic Acids Research, pp1083-1084, vol. 23(6)					
		SINGH-GASSON, et al, Maskless fabrication of light-directed oligonucleotide microarrays using a digital nucromirror array, Nature Biotechnol, 1999, pp. 974-978, vol. 17					
		SINGHVI, et al., Engineering Cell Shapte and Function, Science, 1994, pp696-698, vol.					
Examiner signature		Date 1/12/05					

*EXAMINER: Initial illustrates considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

				Complete if Known			
Substitute for form 1449/PTO				Application Number	10/602,998		
			OSURE	Filing Date	June 23, 2003		
STATE				First Named Inventor	Thomas M. Brennan		
(Use	as many she	ets as neces	sary)	Art Unit	+645 1637		
				Examiner Name	Unknown Chris Besic		
Sheet	23	of	27	Attorney Docket Number	28690-705.302		

		NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				
omen		SOKOLOV, Primer extension technique for the detection of single nucleotide in genomic DNA, Nucleic Acids Res., 1990, pp3671, vol. 18(12)					
		SOSNOWSKI et al., Rapid determination of singel base mismatch mutations in DAN hybrids by direct electric field control, Proc. Natl. Acad. Sci., 1997, pp1119-1123, vol. 94					
		SPIELBERG, et al, N-Acetyltransferases: Phannacogenetics and Clinical Consequences of Polymorphic Drug Metabolism, J. Pharmacokint. Bipharm, 1996, pp509-519, vol. 24(5)					
		STEWARD, Cleavage Methods Following Boc-Based Solid-Phase Peptide Synthesis, Methods in Enzymol, 1997, pp29-44, vol. 289					
		SYVANEN et al, A Primer-Guilded Nucleotide Incorporation Assay in the Genetyping of Apolipoprotein E, Genomics, 1990, pp684-692, vol. 8					
		SYVANEN, From Gels to Chips: 'Minisequencing' Primer Extension for Analysis of Point Mutations and Single Nucleotide Polymorphisms, Human Mutation, 1999, pp1-10, vol. 13					

Examiner signature Date Considered 4/12/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique copy of this form with the communication of applicants.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

,				Com	Complete if Known			
Substitute f	or form 144	19/PTO		Application Number	10/602,998			
			OSURE	Filing Date	June 23, 2003 Thomas M. Brennan			
			LICANT	First Named Inventor				
(Use	as many shee	eis as neces	sary)	Art Unit	1645 1637			
				Examiner Name	-Unknown-Chis Babic			
Sheet	24	of	27	Attorney Docket Number	28690-705.302			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	_T²
OWR		THOMPSON, et al, Synthesis and Applications of Small Molecule Libraries, Chem. Rev., 1996, pp555-600, vol. 96	
		TOSHIMA et al, Recent Progess in O-glycosylation Methods and Its application to Natural Products Synthesis, Chem. Rev, 1993, pp1503-1531, vol. 93	
		TYAGI, et al, Multicolor Molecular Beacons for allele discrimination, Nature Biotechnol, 1998, pp49-53, vol. 16	
		UETZ, et al, A comprehensive analysis of protein-protein interactions in Saccharomyces, Nature, 2000, pp623, vol. 403	
		VAN NESS, et al, The use of oligodeoxynucleofde probes in chaotrope-based hybridization solutions, Nucleic Acids Research, 1991, pp5143-5151, vol. 19(19)	
		VENKATESAN and GREENBERG, Improved Utility of Photolabile Sold Phase Synthesis Supports for the Synthesis of Oligonucleotides Containing 3'-Hydroxyl Termini, J. of Org. Chem, 1996, pp525-529, vol. 61	

Examiner Date Considered signature

*EXAMINER: Initial: reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO). to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
o a collection of information unless it contains a valid OMB control and the

				Complete if Known			
Substitute for form 1449/PTO				Application Number	10/602,998		
			LOSURE	Filing Date	June 23, 2003		
	STATEMENT BY APPLICANT (Use as many sheets as necessary)			First Named Inventor	Thomas M. Brennan		
(Use				Art Unit	1645 1637		
				Examiner Name	Unknown Chris Basic		
Sheet	25	of	27	Attorney Docket Number	2860-705.302		

Examiner Cite Initials* No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
CUMP7	VERMA and ECKSTEIN, MODIFIED OLIGONUCLEOTIDES: Synthesis and Strategy for Users, Annu. Rev. Biochem, 1998, pp99-134, vol. 67	
	WAGNER, et al, Antisense Gene inhibition by oligonucleotides containing C-5 propyne pyrimidines, Science, 1993, pp1510-1513, vol. 260	
	WALKER, Empirical Aspects of Strand Displacement Amplication, PCR Methods Appl., 1993, pp 1-6, vol. 3	
	WANG, Solid Phase Synthesis of Protected Peptide via Photolytic Clevage of the armethylphenacyl Ester Anchoring Linkage, J. Org. Chem, 1976, p3258, vol. 41	
	WANG, et al, A New Base-Labile Anchoring Group for Polymer-Supported Oligosaccharide Synthesis, Chem. Lett, 1995, pp273-274	
	WANG, D., et al, Large-Scale Identification, Mapping, and Genotyping of Single-Nucleotide Polymorphisms in the Human Genome, Science, 1998, 1077-1082, vol. 280	
	WETMUR, DNA Probes: Applicationis of the Principles of Nucleic Acid Hybridization, Critical Reviews in Biochemistry and Molecular Biology, 1991, pp227- 259, vol. 26	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Hoder the panerwork Reduction Act of 1995, no po

				Complete if Known			
Substitute	for form 144	19/PTO		Application Number	10/602,998	3	
INFORM	MATION	DISC	LOSURE	Filing Date	June 23, 2003		
			LICANT	First Named Inventor	Thomas M		
(Use	as many shee	ets as nece	essary)	Art Unit	-1645-	1637	
	•			Examiner Name	Linknown	Chris	Bas'c
Sheet	26	of	27	Attorney Docket Number	28690-705	302	

Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
ang	WIEDMANN, et al., Ligase Chain Reaction (LCR) - Overview and Applications, PCR Methods Appl, 1994, pp51-64, vol. 3	
	WHITE, High-Throughput Screening in Drug Metabolism and Pharmacokinetic Support of Drug Discovery, Annu. Rev. Pharmacol. Toxicol, 2000, pp133-157, vol. 40	
	WU, et al, The Ligation Amplification Reaction (LAR) - Amplification of Specific DNA Sequences Using Sequential Rounds of Template-Dependent Ligation, Genomics, 1989, pp560-569, vol. 4	
	YAMADA, et al, An Efficient Synthesis of Sialoglycoconjugtes on a Peptidase- Sensitive Polymer Support, Tetrahedron Lett., 1995, pp9493-9496, vol. 36	
	YAN et al, Glycosylation on the Merrifield Resin Using Anomerica Sulfoxides, J. Am. Chem. Soc, 1994, pp6953-6954, vol. 116	•
	YOO et al, Synthesis of Oligonucleotides Containing 3'-Alkyl Carboxylic Acids Using Universal, Photolabile Solid Phase Synthesis Supports, J. of Org. Chem, 1995, pp3358-3364, vol. 60	
7	YOUNG, Biomedical Discovery with DNA Arrays, Cell, 2000, pp9-15, vol. 102	

*EXAMINER: Initial in teleschee considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Considered

*CAMMNEK: Initial irreference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

				Complete if Known			
Substitute	for form 14	49/PTO		Application Number	10/602,998		
INFORMATION DISCLOSURE			LOSURE	Filing Date	June 23, 2003		
STATEMENT BY APPLICANT		First Named Inventor	Thomas M. Brennan				
(Use as many sheets as necessary)			ssary)	Art Unit	1645 1637		
				Examiner Name	Unknown Chris Bobic		
Sheet	27	of	27	Attorney Docket Number	28690-705.302		

Examiner Initials*	Cite No. 1	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
CARP		Zheng et al, Solid Support Oligosaccharide Synthesis: Construction of B-Linked Oligosaccharides by Coupling by Glycal Derived Thioethyl Glycosyl Donors, J. Org. Chem., 1998, pp 1126-1130, vol. 63				
•		·				
	·					
			_			

*EXAMINER: Initial ideference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Date

Considered

considered. Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option

Examiner